<DOC>
	<DOCNO>NCT01204177</DOCNO>
	<brief_summary>This study investigate safety efficacy combination therapy BAY86-9766 sorafenib patient liver cancer . Safety determine laboratory evaluation . Efficacy combination BAY86-9766 sorafenib determine disease control rate , overall survival , time progression , response rate duration response .</brief_summary>
	<brief_title>Assessing BAY86-9766 Plus Sorafenib Treatment Liver Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Male Female age &gt; /= 18 year age Life expectancy &gt; /= 12 week Histologically cytologically confirm diagnosis HCC , unresectable advanced metastatic Liver function status ChildPugh class A. ChildPugh status base clinical finding laboratory result screen period Eastern Cooperative Oncology Group performance status ( ECOG PS ) 0 1 Patients must least one na√Øve ( previously treat locoregional therapy ) unidimensional measurable lesion CT MRI accord RECIST 1.1 Adequate bone marrow , liver renal function Previous concurrent cancer HCC , except cervical carcinoma situ , basal cell carcinoma , superficial bladder tumor . History cardiac disease : Congestive heart failure ( CHF ) , unstable angina , arrhythmia , Uncontrolled hypertension Clinically significant GI bleeding ( CTCAE grade 3 high ) within 30 day Renal failure require hemo peritoneal dialysis Known human immunodeficiency virus ( HIV ) infection Known history symptomatic metastatic brain meningeal tumor History organ allograft . History interstitial lung disease ( ILD ) . Excluded previous therapy medication : Prior use systemic anticancer treatment HCC include cytotoxic chemotherapy , target agent , experimental therapy Radiotherapy within 4 week prior start study treatment Any investigational agent within 4 week first dose study treatment Major surgery within 4 week start study Concomitant use strong inhibitor strong inducer CYP3A4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Hepatocellular carcinoma ( HCC )</keyword>
	<keyword>MEK inhibitor</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Disease control rate ( DCR )</keyword>
	<keyword>Safety</keyword>
</DOC>